Number of patients |
100 |
64 |
36 |
- |
Oxygen therapy FiO2 |
Oxygen therapy FiO2 |
Oxygen therapy FiO2 |
Oxygen therapy FiO2 |
Oxygen therapy FiO2 |
FiO2 on admission
21%
30%
40%
50%
100%
|
54 (54%)
29 (29%)
7 (7%)
4 (4%)
6 (6%)
|
42 (66%)
14 (22%)
6 (9%)
1 (2%)
1 (2%)
|
12 (33%)
15 (42%)
1 (3%)
3 (8%)
5 (14%)
|
0.001
|
Highest FiO2 during admission
21%
30%
40%
50%
100%
High flow oxygen
|
32 (32%)
26 (27%)
10 (10%)
5 (5%)
21 (21%)
4 (4%)
|
28 (44%)
20 (31%)
8 (12%)
2 (3%)
4 (6%)
2 (3%)
|
4 (12%)
6 (18%)
2 (6%)
3 (9%)
17 (50%)
2 (6%)
|
<0.001
|
Prone positioning |
5 (5%) |
0 (0%) |
5 (14%) |
0.002 |
Medical treatment |
|
|
|
|
Only symptomatic |
31 (31%) |
18 (28%) |
13 (36%) |
0.41 |
Medication†|
69 (69%) |
46 (72%) |
23 (64%) |
|
Azithromycin
HCQ + azithromycin
HCQ + azithromycin + Lopinavir/r
|
2 (3%)
66 (96%)
1 (1%)
|
0 (0%)
46 (100%)
0 (0%)
|
2 (9%)
20 (87%)
1 (4%)
|
0.04
|
Days from the onset of symptoms to start of treatment |
9 [4] |
9
[4] |
7 [7] |
0.08 |
Intravenous antibiotics |
26 (26%) |
13 (20%) |
13 (36%) |
0.08 |
Glucocorticoids |
12 (12%) |
6 (9%) |
6 (17%) |
0.28 |